Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395332 | 0.89 | MRGPRX4 (0.46) | SMN1; SMN2MRGPRX4PTGER4DAOMEN1 | |
| SCHEMBL6397512 | 0.88 | MRGPRX4 (0.47) | SMN1; SMN2MRGPRX4PTGER4DAOMEN1 | |
| SCHEMBL6402998 | 0.87 | HRH3 (0.47) | HRH3NR4A2 | |
| SCHEMBL6395112 | 0.84 | ALDH1A1 (0.51) | SMN1; SMN2PTGER4MEN1KMT2A | |
| SCHEMBL10328542 | 0.82 | MRGPRX4 (0.50) | SMN1; SMN2HSD17B10MRGPRX4PTGER4NR4A2 | |
| SCHEMBL6397218 | 0.81 | DAO (0.55) | DAOMEN1KMT2A | |
| SCHEMBL10328548 | 0.80 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL10494168 | 0.80 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL6900481 | 0.80 | MEN1 (0.42) | PTGER4MEN1KMT2A | |
| SCHEMBL10328605 | 0.79 | MEN1 (0.48) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | claimed |
| US-6552073-B1 | As anti-proliferative agent; for therapy of cancer | EXONHIT THERAPEUTICS SA (FR) | 2003-04-22 | — | — | US | claimed |
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| EP-1480966-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | Exonhit Therapeutics S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003074508-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | EXONHIT THERAPEUTICS SA (FR) | 2003-09-12 | — | — | WO | disclosed |
| US-6552073-B1 | As anti-proliferative agent; for therapy of cancer | EXONHIT THERAPEUTICS SA (FR) | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | SMN1; SMN2 1723/4885HSD17B10 1433/4885MRGPRX4 3301/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | SMN1; SMN2 4827/4885HSD17B10 2224/4885MRGPRX4 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.